Nantahala Capital Management LLC Buys Shares of 486,684 Amylyx Pharmaceuticals, Inc. $AMLX

Nantahala Capital Management LLC acquired a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 486,684 shares of the company’s stock, valued at approximately $8,740,845. Nantahala Capital Management LLC owned 0.44% of Amylyx Pharmaceuticals as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. BlackRock Inc. bought a new stake in Amylyx Pharmaceuticals in the second quarter valued at $158,534,000. Adage Capital Partners GP L.L.C. raised its holdings in shares of Amylyx Pharmaceuticals by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after purchasing an additional 3,102,395 shares during the period. Perceptive Advisors LLC boosted its position in shares of Amylyx Pharmaceuticals by 0.4% during the 2nd quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock worth $50,654,000 after purchasing an additional 28,017 shares in the last quarter. TCG Crossover Management LLC boosted its position in shares of Amylyx Pharmaceuticals by 5.0% during the 3rd quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock worth $84,853,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Amylyx Pharmaceuticals by 10.1% in the 4th quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock valued at $70,123,000 after buying an additional 531,162 shares during the period. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX opened at $34.74 on Friday. The company has a market capitalization of $3.87 billion, a PE ratio of -24.29 and a beta of -0.21. The business has a fifty day moving average price of $22.53 and a two-hundred day moving average price of $17.49. Amylyx Pharmaceuticals, Inc. has a 1 year low of $9.15 and a 1 year high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Sell-side analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Wall Street Analyst Weigh In

AMLX has been the subject of several recent research reports. Mizuho boosted their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Citigroup increased their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. HC Wainwright boosted their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $36.50.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Profile